Daily Endocrinology Research Analysis
Analyzed 96 papers and selected 3 impactful papers.
Summary
Analyzed 96 papers and selected 3 impactful articles.
Selected Articles
1. Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m
In a 24-week randomized, double-blind, placebo-controlled phase 2 trial (n=80), mazdutide 9 mg induced a -12.78% mean weight change vs +1.80% with placebo and improved cardiometabolic risk factors. Adverse events were mainly mild to moderate gastrointestinal symptoms.
Impact: Demonstrates robust efficacy of a dual glucagon/GLP-1 receptor agonist with sizable weight loss and metabolic benefits, advancing next-generation obesity therapeutics.
Clinical Implications: If confirmed in larger and longer RCTs, mazdutide could expand pharmacologic options for obesity, potentially benefiting patients needing >10% weight loss with additional metabolic gains.
Key Findings
- Mazdutide 9 mg achieved -12.78% mean weight change at 24 weeks vs +1.80% with placebo (treatment difference -14.58%, p<0.0001).
- 81.7% of participants on mazdutide achieved ≥5% weight loss; none did with placebo.
- Cardiometabolic risk factors improved more with mazdutide; GI adverse events (nausea 50%, diarrhea 38.3%, vomiting 36.7%) were mostly mild–moderate.
Methodological Strengths
- Randomized, double-blind, placebo-controlled phase 2 design with prespecified outcomes
- ClinicalTrials.gov registration and clear between-group effect estimates with confidence intervals
Limitations
- Small sample size (n=80) and 24-week duration limit long-term efficacy and safety inference
- Single-country population may limit generalizability across ethnicities and healthcare systems
Future Directions: Phase 3 trials should assess long-term weight maintenance, cardiovascular and hepatic outcomes, quality of life, and comparative effectiveness vs GLP-1/GIP co-agonists.
BACKGROUND: Once-weekly dual glucagon and glucagon-like peptide-1 receptor agonist mazdutide, administered at 4 and 6 mg, provides substantial weight loss in Chinese adults with overweight or obesity. This trial aimed to evaluate the efficacy and safety of mazdutide 9 mg in Chinese adults with obesity. METHODS: In this randomized, double-blind, placebo-controlled phase 2 trial (NCT01904913), participants with a body mass index (BMI) ≥30 kg/m FINDINGS: Eighty participants were randomized and received mazdutide 9 mg (n = 60) or placebo (n = 20). At week 24, the mean percentage change in weight from baseline was -12.78% with mazdutide 9 mg and 1.80% with placebo (treatment difference: -14.58% [95% confidence interval (CI) -18.00, -11.16], p < 0.0001). Weight reduction ≥5% was achieved by 81.7% of participants with mazdutide after 24-week treatment, while no participants with placebo achieved this threshold. Mazdutide treatment was associated with greater improvements in cardiometabolic risk factors vs. placebo. The most common adverse events included nausea (50.0% with mazdutide vs. 0% with placebo), diarrhea (38.3% vs. 10.0%), and vomiting (36.7% vs. 10.0%), predominantly mild to moderate in severity. CONCLUSIONS: Mazdutide 9 mg was safe and led to substantial weight reductions in Chinese adults with a BMI ≥ 30kg/m FUNDING: This study was sponsored by Innovent Biologics.
2. Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.
In this ITT post hoc analysis of 9,650 participants with T2D and ASCVD and/or CKD, oral semaglutide led to early (13-week) and sustained improvements through 156 weeks in HbA1c, body weight, systolic BP, hsCRP, and triglycerides vs placebo. LDL-C and diastolic BP showed no significant differences.
Impact: Connects the observed CV event reduction to durable improvements in established risk factors, strengthening mechanistic plausibility and informing comprehensive risk management.
Clinical Implications: Supports use of oral semaglutide for multi-risk factor optimization in high-risk T2D, with additive benefits beyond standard care and potential alignment with cardio-renal protection strategies.
Key Findings
- At week 156, ETDs favored semaglutide for HbA1c (-0.47 pp), body weight (-3.26%), SBP (-1.83 mm Hg), and pulse pressure (-2.17 mm Hg).
- ETRs favored semaglutide for hsCRP (0.77), non-HDL-C (0.98), HDL-C (1.01), and triglycerides (0.94); no significant differences for LDL-C or DBP.
- Early (13-week) improvements in glycemia, weight, BP, hsCRP, and lipids were sustained over the trial duration.
Methodological Strengths
- Large multicenter double-blind RCT dataset with ~47.5 months mean follow-up and ITT analysis
- Comprehensive cardiometabolic endpoints with consistent early and sustained effects
Limitations
- Post hoc secondary analysis; not powered for causal mediation between risk factor changes and MACE
- No significant change in LDL-C or diastolic BP; potential residual confounding in biomarker analyses
Future Directions: Formal mediation analyses and head-to-head trials vs other GLP-1–based agents or SGLT2 inhibitors could clarify mechanisms and optimize combination strategies.
IMPORTANCE: Individuals with type 2 diabetes (T2D) are at high risk of atherosclerotic cardiovascular disease (ASCVD). In the SOUL randomized clinical trial, once-daily oral semaglutide reduced risk of major adverse cardiovascular (CV) events by 14% vs placebo in people with T2D and ASCVD and/or chronic kidney disease (CKD) receiving standard of care (SoC); however, whether oral semaglutide modifies recognized CV risk factors in the long term is unclear. OBJECTIVE: To investigate whether treatment with oral semaglutide was associated with changes in ASCVD risk factors vs placebo. DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis comprises post hoc intention-to-treat analyses of the SOUL (A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes) double-blind multicenter randomized clinical trial (randomization 1:1 to oral semaglutide or placebo) among adults with T2D and ASCVD and/or CKD receiving SoC. Participants underwent randomization from June 2019 to March 2021, with a mean (SD) of 47.5 (10.9) months of follow-up, and data were analyzed from February to December 2025. INTERVENTION(S): Participants were treated with either once-daily oral semaglutide (maximum dose, 14 mg) or placebo, in addition to standard care. MAIN OUTCOMES AND MEASURES: The primary outcome was the association of oral semaglutide vs placebo with glycated hemoglobin (HbA1c), body weight, and blood pressure (BP) using estimated treatment differences (ETDs) and with high-sensitivity C-reactive protein (hsCRP) and lipid plasma levels using estimated treatment ratios (ETRs).
3. Impact of hypothyroidism and hyperthyroidism on endometrial cancer incidence: results from a large population-based cohort study.
In a nationwide cohort of over one million women with 17.5 years median follow-up, hypothyroidism was associated with higher endometrial cancer incidence (overall HR 1.53; type I HR 1.64), consistent across menopausal status and time since diagnosis. Hyperthyroidism showed no significant association.
Impact: Clarifies an endocrine–oncology link at scale, informing risk stratification and hypothesis generation on thyroid–endometrium pathways.
Clinical Implications: While absolute risk increase is modest, clinicians should consider endometrial cancer vigilance in women with hypothyroidism, especially for type I histology, alongside standard risk factors.
Key Findings
- Among 1,057,937 women (median follow-up 17.5 years), 1,159 developed endometrial cancer.
- Hypothyroidism was associated with higher incidence of endometrial cancer (HR 1.53, 95% CI 1.22–1.93) and type I tumors (HR 1.64, 95% CI 1.12–2.41).
- Hyperthyroidism showed no significant association (HR 1.14, 95% CI 0.80–1.62); absolute risk difference by age 60 was modest and not statistically significant.
Methodological Strengths
- Nationwide population-based cohort with >1 million participants and long follow-up
- Robust statistical approach including Cox models, landmark analysis, and pseudo-observations for absolute risk differences
Limitations
- Potential residual confounding and misclassification of thyroid status or treatment in registry data
- Modest absolute risk difference limits immediate screening policy changes
Future Directions: Mechanistic and longitudinal studies should assess thyroid hormone pathways, endometrial proliferation, and the role of treatment (e.g., levothyroxine) on cancer risk.
The limited number of studies examining the association between thyroid diseases and endometrial cancer have yielded inconsistent findings. The study aimed to examine the association between hypothyroidism and hyperthyroidism and the risk of endometrial cancer using comprehensive nationwide register data from Denmark. We conducted a population-based cohort study including 1,057,937 women born in Denmark between 1960 and 1997. Information on thyroid disease diagnoses, cancer diagnoses, covariates, migration, and vital status was obtained from nationwide Danish health and administrative registers. Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for endometrial cancer overall and for type I tumors. A landmark analysis examined risks associated with exposures before age 40, and pseudo-observation methods estimated absolute risk differences. During a median follow-up of 17.5 years, 1,159 women were diagnosed with endometrial cancer. Women with hypothyroidism had a higher rate of overall endometrial cancer (HR: 1.53, 95% CI: 1.22-1.93) and type I tumors (HR: 1.64, 95% CI: 1.12-2.41). These associations were consistent across subgroups defined by menopausal status and time since diagnosis. No association was observed for hyperthyroidism (HR: 1.14, 95% CI: 0.80-1.62). In the landmark analysis, hypothyroidism remained associated with an increased endometrial cancer rate, but the absolute risk difference by age 60 was modest and not statistically significant. In conclusion, hypothyroidism was associated with a modestly increased rate of endometrial cancer, while no association was observed for hyperthyroidism. These findings support further investigation into thyroid function and endometrial carcinogenesis.